Lianhua Qingke for the Rehabilitation of Patient With Omicron Infection
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The patients with Omicron infection usually have fever, respiratory symptoms, tachycardia,
headache, toothache, muscle soreness, physical decline, and so on, while others are
asymptomatic patients. It is urgent to find drugs to improve the long-term rehabilitation of
symptomatic patients with Omicron infection and decrease the duration of viral shedding in
both symptomatic and asymptomatic patients. This study aims to investigate the efficacy and
safety of Lianhua Qingke tablets in patients with Omicron infection. The duration of viral
shedding and symptoms will be evaluated. 6-month follow-up will be performed to evaluate the
effect of Lianhua Qingke on long-term rehabilitation of all symptoms induced by Omicron
infection, as well as infection events.